Karl Gaffney

15PUBLICATIONS
36CO-AUTHORS
PhysiotherapyRheumatology and arthritisHealth economicsBiomechanicsClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

|Nov 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Helena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil

|Apr 25, 2025
What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?

Fernando Zanghelini, Georgios Xydopoulos, Stephanie Howard Wilsher

|Aug 21, 2024
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis.

Jake Weddell, Stephanie R Harrison, Alexander N Bennett

|Jun 04, 2024
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.

Maureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen

|Sep 04, 2023
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.

Karl Gaffney, Nicola Gullick, Kirsten MacKay

Pageof 3

Frequent Collaborators

7 joint publications

Helena Marzo-Ortega

6 joint publications

Gareth T Jones

6 joint publications

Raj Sengupta

5 joint publications

Stefan Siebert